Axsome (AXSM) said the results support the efficacy and safety of AXS-05 in the treatment of agitation in Alzheimer's patients. The company plans to submit a New Drug Application to the FDA for ...

Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...

Experts are expecting this Memorial Day weekend to be the busiest yet, with nearly 44 million Americans projected to travel ...

drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s patients. Axsome, meanwhile, recently reported positive results in its ...

The FDA approved Rexulti for agitation associated with dementia due to Alzheimer’s in 2023. Lundbeck cited penetration of the U.S. Alzheimer’s market as a driver of growth of Rexulti over the first ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday.Don't Miss Our New ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

in the treatment of Alzheimer disease (AD) agitation. According to the company, the ACCORD-2, ADVANCE-2, and ACCORD-1 studies demonstrated statistically significant efficacy with AXS-05, with plans to ...

is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer’s (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has ...